button bars forest bayes pooled summary circles
 
deaths (OS)progression or deaths (PFS)RFS/DFS

mHNSCC - L2 - all population metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - all population

versus Standard of Care (SoC)
durvalumab alone vs. Standard of Care (SoC) 1 certainty unassessable-11% certainty unassessable+2%-
durvalumab plus tremelimumab vs. Standard of Care (SoC) 1 certainty unassessable+4% certainty unassessable+9%-
nivolumab alone vs. Standard of Care (SoC) 1 certainty unassessablestatistically conclusive-28% certainty unassessable-10%-
pembrolizumab alone vs. Standard of Care (SoC) 1 certainty unassessablestatistically conclusive-18% certainty unassessable-4%-

mHNSCC - L2 - PDL1 negative metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - PDL1 negative

versus durvalumab alone
durvalumab plus tremelimumab vs. durvalumab alone 1 certainty unassessable-1% certainty unassessable+13%-
versus tremelimumab
durvalumab plus tremelimumab vs. tremelimumab 1 certainty unassessable-26% certainty unassessable-25%-

mHNSCC - L2 - PDL1 positive metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - PDL1 positive

versus Standard of Care (SoC)
pembrolizumab alone vs. Standard of Care (SoC) 1 certainty unassessablestatistically conclusive-24% certainty unassessable+1%-

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons